✦ LIBER ✦

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Scribed by Michael A. Gold; William E. Brady; Heather A. Lankes; Peter G. Rose; Joseph L. Kelley; Koen De Geest; Marta A. Crispens; Kimberly E. Resnick; Stephen B. Howell

Book ID: 113964109
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 257 KB
Volume: 125
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2012.03.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of AMG 102 (rilotu

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Martin, Lainie P.; Sill, Michael; Shahin, Mark S.; Powell, Matthew; DiSilvestro, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 246 KB

A phase II study of vorinostat in the tr

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Susan C. Modesitt; Michael Sill; James S. Hoffman; David P. Bender 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 251 KB

A phase II evaluation of mifepristone in

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 162 KB

A phase II evaluation of lapatinib in th

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

✍ Agustin A. Garcia; Michael W. Sill; Heather A. Lankes; Andrew K. Godwin; Robert 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Phase II evaluation of dasatinib in the

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

A phase II evaluation of belinostat and

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

✍ Don S. Dizon; John A. Blessing; Richard T. Penson; Richard D. Drake; Joan L. Wal 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 197 KB